Scientific & Medical History
The science of cannabis has a surprisingly rich history — from ancient pharmacopeias to the 1964 isolation of THC, to the discovery of the endocannabinoid system, one of the most significant findings in 20th-century biology.
Early Pharmacology (Ancient – 1800s)
The Shennong Bencao Jing (Divine Farmer's Materia Medica, ~200 CE) recommends cannabis for pain, gout, rheumatism, constipation, and malaria. The Egyptian Ebers Papyrus (~1550 BCE) mentions it for inflammation. In 1839, Irish physician William Brooke O'Shaughnessy published a landmark paper after studying cannabis medicine in India — demonstrating efficacy for pain, muscle spasms, and cholera-induced convulsions. This introduced cannabis to Western medicine. By 1850, the US Pharmacopeia listed cannabis as a recognized treatment, and major pharmaceutical companies sold cannabis tinctures commercially until the 1937 prohibition.
Isolation of THC (1964)
The modern scientific era began when Israeli chemist Raphael Mechoulam and colleague Yechiel Gaoni at the Hebrew University of Jerusalem isolated, identified, and synthesized delta-9-tetrahydrocannabinol (THC) in 1964 — the primary psychoactive compound in cannabis. This was a monumental breakthrough: for the first time, researchers could study a pure, known compound rather than the whole plant. Mechoulam had earlier isolated CBD in 1963. He would go on to make three more landmark discoveries, earning the title "father of cannabis research" before his death in 2023 at age 92.
Discovery of the Endocannabinoid System (1988–1993)
The most consequential discovery in cannabis science — and arguably in neuroscience — was the endocannabinoid system (ECS). In 1988, Allyn Howlett and William Devane discovered CB1 receptors in rat brains — specific binding sites for THC. This implied the brain had its own cannabis-like system. In 1992, Mechoulam's team isolated anandamide (from the Sanskrit ananda, meaning bliss) — the first endogenous cannabinoid, the brain's own THC equivalent. CB2 receptors were identified in 1993. The ECS — regulating mood, pain, appetite, memory, immune function, and sleep — is now recognized as one of the most widespread receptor systems in the human body, present in virtually every organ.
CBD Research & the First FDA Approval (1990s–2018)
CBD was first isolated in 1940 by Roger Adams at the University of Illinois, but its full significance wasn't understood for decades. Research in the 1990s began revealing its anticonvulsant, anti-inflammatory, and anxiolytic properties without psychoactivity. GW Pharmaceuticals (UK) began developing Epidiolex — a purified CBD oral solution for treatment-resistant childhood epilepsy (Dravet syndrome and Lennox-Gastaut syndrome) — in the early 2000s. In 2018, Epidiolex became the first FDA-approved cannabis-derived pharmaceutical. Its approval was a watershed moment, legitimizing cannabis as medicine in the eyes of federal regulators for the first time since 1942.
The Research Gap & What Comes Next
Schedule I classification made rigorous cannabis research in the US nearly impossible for 50 years. Researchers needed DEA licenses, could only access cannabis from a single federally licensed farm at the University of Mississippi (notorious for producing poor-quality material unlike anything sold in dispensaries), and struggled to obtain institutional approval. This created a massive evidence gap. The DEA expanded licensed cultivators in 2021. The proposed rescheduling to Schedule III (2024) would transform research access — allowing pharmaceutical-grade studies, clinical trials, and eventually a new generation of cannabis-derived medicines.
- ✓O'Shaughnessy introduced cannabis to Western medicine: 1839
- ✓CBD isolated: Roger Adams, 1940
- ✓THC isolated: Mechoulam & Gaoni, 1964
- ✓CB1 receptors discovered: Howlett, 1988
- ✓Anandamide discovered: Mechoulam, 1992
- ✓First FDA cannabis drug (Epidiolex): 2018
- ✓DEA expanded cultivator licenses: 2021